When the FRAX® test is applied to controlled clinical trials

Fiore, Carmelo Erio and Gaudio, Agostino (2012) When the FRAX® test is applied to controlled clinical trials. Clinical cases in mineral and bone metabolism, 9 (3). pp. 135-137. ISSN 1971-3266

Preview

PDF portiere.pdf - Published Version Download (528kB)

Abstract

FRAX® is a computer-based algorithm developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases in Sheffield (UK). This algorithm calculates fracture probability from easily obtained clinical risk factors in men and women: age, sex, body mass index and dichotomized variables comprising prior fragility fracture, parental history of hip fracture, current tobacco smoking, use of long-term oral glucocorticoid, rheumatoid arthritis, other causes of secondary osteoporosis and high alcohol consumption (femoral neck bone mineral density can be optionally input to enhance fracture risk prediction). The output of FRAX® is the 10-year probability of a major osteoporotic fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip fracture. Recently various Authors have re-evaluated the effectiveness of drugs approved for postmenopausal osteoporosis to test whether they are more effective in women with higher FRAX® probabilities

Item Type:	Article
Uncontrolled Keywords:	FRAX®; alendronate; clodronate; strontium ranelate; raloxifene; bazedoxifene; denosumab
Subjects:	600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 611 Anatomia; Citologia; Istologia umana > 611.7 Sistema muscoloscheletrico, tegumento
Depositing User:	Danilo Dezzi
Date Deposited:	03 Dec 2013 11:01
Last Modified:	03 Dec 2013 11:01
URI:	http://eprints.bice.rm.cnr.it/id/eprint/6069

Actions (login required)

View Item